ClinicalTrials.gov
public full text
Public Domain
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure
This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart Failure#172492
- Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.#1010380
- Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment#148652
- Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction#825826
- Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure#836393
Record · ID 910283
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive